Cholesterol-lowering drugs: FDA has approved Praluent, a PCSK9 inhibitor, to treat hypercholesterolemia
The FDA ( Food and Drug Administration ) has approved Praluent ( Alirocumab ) injection, the first cholesterol-lowering treatment approved in a new class of drugs known as proprotein convertase subtilisin kexin type 9 ( PCSK9 ) inhibitors.
Praluent is approved for use in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia ( HeFH ) or patients with clinical atherosclerotic cardiovascular disease such as myocardial infarctions or strokes, who require additional lowering of LDL cholesterol.
Heterozygous familial hypercholesterolemia is an inherited condition that causes high levels of low-density lipoprotein ( LDL ) cholesterol.
A high level of LDL cholesterol in the blood is linked to cardiovascular disease.
Alirocumab is an antibody that targets a specific protein, called PCSK9, which works by reducing the number of receptors on the liver that remove LDL cholesterol from the blood. By blocking PCSK9’s ability to work, more receptors are available to get rid of LDL cholesterol from the blood and, as a result, lower LDL cholesterol levels.
The efficacy and safety of Praluent were evaluated in five placebo-controlled trials, involving 2,476 participants exposed to Praluent.
All participants had heterozygous familial hypercholesterolemia or were otherwise at high risk for myocardial infarction or stroke, and were taking maximally tolerated doses of a statin, with or without other lipid-modifying therapies.
Participants taking Praluent had an average reduction in LDL cholesterol ranging from 36 to 59%, compared to placebo.
Multiple clinical trials have demonstrated that statins lower the risk of having a myocardial infarction or stroke. A trial evaluating the effect of adding Alirocumab to statins on reducing cardiovascular risk is ongoing.
The most common side effects of Praluent include itching, swelling, pain, or bruising where injection is given, nasopharyngitis, and flu. Allergic reactions, such as hypersensitivity vasculitis ( a skin rash usually appearing as purple-colored spots on the skin associated with inflammation of small blood vessels ) and hypersensitivity reactions requiring hospitalization, have been reported with the use of Praluent.
Patients should stop using Praluent and get medical help if they experience symptoms of a serious allergic reaction. ( Xagena )
Source: FDA, 2015
Durable and potent LDL-cholesterol reduction with Inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Results from a prespecified analysis of pooled data from three phase III studies evaluating the safety and efficacy of Inclisiran,...
Praluent to prevent myocardial infarction, stroke and unstable angina requiring hospitalization, approved by FDA
The FDA ( U.S. Food and Drug Administration ) has approved Praluent ( Alirocumab ) to reduce the risk of...
Lorviqua for treatment of adult patients with ALK-positive advanced non-small cell lung cancer, previously treated with one or more ALK tyrosine kinase inhibitors: approved in European Union
The European Commission ( EC ) has granted conditional marketing authorization for Lorviqua ( Lorlatinib, available in the U.S., Canada...
Lorlatinib in patients with previously treated ALK+ advanced non-small cell lung cancer: efficacy and safety
Despite advancement of 2nd generation ALK tyrosine kinase inhibitors ( TKIs ), patients with ALK+ non-small cell lung cancer ...
Heterozygous familial hypercholesterolemia: individualized low-density lipoprotein cholesterol reduction with Alirocumab titration strategy
Patients with heterozygous familial hypercholesterolemia ( HeFH ) who completed the double-blind ODYSSEY LONG TERM parent trial and subsequently enrolled...
Long-term safety and efficacy of Alirocumab in patients with heterozygous familial hypercholesterolemia
ODYSSEY OLE ( open-label extension ) has included patients diagnosed with heterozygous familial hypercholesterolemia ( HeFH ), receiving maximally tolerated...
Aging is associated with an increased incidence of cancer and cardiovascular disease. Researchers recently used whole-exome sequencing data to identify...
GLAGOV trial: lowering LDL cholesterol with Evolocumab, a PCSK9 inhibitor, impacts underlying atherosclerotic disease on top of optimized statin therapy
The phase 3 GLAGOV ( GLobal Assessment of Plaque ReGression with a PCSK9 AntibOdy as Measured by IntraVascular Ultrasound )...
Heterozygous familial hypercholesterolemia: 63% of patients treated with Alirocumab no longer required apheresis
Positive results from the phase 3 ODYSSEY ESCAPE trial evaluating Alirocumab ( Praluent ) injection in patients with an inherited...
The FDA ( Food and Drug Administration ) has approved the Repatha ( Evolocumab ) Pushtronex system ( on-body infusor...